|Year : 2017 | Volume
| Issue : 3 | Page : 218-222
Correlation of various maternal factors with exaggerated hyperbilirubinemia of the newborn
Sneha Taneja1, Vineeta Pande1, Harish Kumar2, Sharad Agarkhedkar1
1 Department of Paediatrics, Dr. D. Y. Patil Medical College and Hospital, Pune, Maharashtra, India
2 Department of Paediatrics, Jawaharlal Nehru Medical College, Wardha, Maharashtra, India
|Date of Web Publication||2-Feb-2018|
Dr. Sneha Taneja
House No. 350, Sector.6, Panchkula, Haryana
Source of Support: None, Conflict of Interest: None
Background: Maternal factors could help determine the potential incidence of hyperbilirubinemia. This study was performed with the purpose of establishing the role of the various maternal factors previously indicated as being responsible for exaggerated physiological hyperbilirubinemia in term neonates with serum bilirubin level of 12 mg/dL or more. Materials and Methodology: It was a prospective, cross-sectional study conducted from July 2012 to August 2014 in Pimpri, Pune. A total of 2000 healthy term deliveries were screened, out of which 100 neonates with exaggerated hyperbilirubinemia were included. Data were collected with maternal information. The data were analyzed using t-test (for parametric distributions). Results: During the period of study, 330 babies out of 2000 deliveries had achieved the serum bilirubin level of >12 mg/dL. Thus, the prevalence of exaggerated neonatal hyperbilirubinemia in the current study was 16.5%. There is strong association between maternal infection and serum bilirubin even when only 5 mothers had infection (Z = 2.31 and P < 0.05), whereas no correlation was found with maternal diabetes mellitus, toxemia, and oxytocin infusion. Conclusions: Maternal infection was found to have a significant effect on neonatal exaggerated hyperbilirubinemia. Therefore, interventions should be prioritized to prevent maternal sepsis. The first approach targets facility-based deliveries and requires increased provision and uptake of proper antenatal care early in pregnancy.
Keywords: Diabetes mellitus, hyperbilirubinemia, maternal infections, oxytocin, toxemia
|How to cite this article:|
Taneja S, Pande V, Kumar H, Agarkhedkar S. Correlation of various maternal factors with exaggerated hyperbilirubinemia of the newborn. J Datta Meghe Inst Med Sci Univ 2017;12:218-22
|How to cite this URL:|
Taneja S, Pande V, Kumar H, Agarkhedkar S. Correlation of various maternal factors with exaggerated hyperbilirubinemia of the newborn. J Datta Meghe Inst Med Sci Univ [serial online] 2017 [cited 2021 Dec 9];12:218-22. Available from: http://www.journaldmims.com/text.asp?2017/12/3/218/224712
| Introduction|| |
Hyperbilirubinemia is the most common problem experienced in the immediate neonatal period. Yet despite years of investigation, many aspects of neonatal jaundice remain unexplained. Although the metabolism of bilirubin is now better understood, the mechanism involved in the evolution of nonhemolytic neonatal hyperbilirubinemia is still unclear.
Approximately 60% term newborn and 80% preterm become clinically jaundiced in the first week of life. The incidence varies with different study group. Physiological jaundice is a normal occurrence between the 2nd and 4th day of life and appears in approximately 50% of all full-term newborns. Bilirubin levels may reach 6–10 mg/dL and resolution generally occurs during the 7th or 8th day. A bilirubin level exceeding 12 mg/dL for the full-term infant is suggestive of more than normal physiology and would be considered exaggerated hyperbilirubinemia (Behrman).
The present study was performed with the purpose of establishing the role of the various maternal factors previously indicated as being responsible for exaggerated physiological hyperbilirubinemia in term neonates with serum bilirubin level of 12 mg/dL or more.
Maternal age was found to be associated with the incidence of neonatal hyperbilirubinemia by some of the earlier workers. Wood et al. found a reduction of jaundice as maternal age advanced. In their study, clinical jaundice was found in 90.5% of babies with maternal age under 30 years, while it was 79.5% in babies with maternal age over 30 years.
Another previously suspected variable, parity of mother was not associated with neonatal jaundice in the study done by Shalinn. Gestational age was found to have influence on neonatal jaundice. Wood et al. observed a gradual reduction of jaundice as gestation advances. Hyperbilirubinemia has been reported to occur with increased frequency in infants of insulin-dependent diabetic mothers.,
Earlier studies on neonatal jaundice have given an impression that preeclamptic toxemia and even uncomplicated hypertension during pregnancy have a marked influence in reducing neonatal jaundice. Wood et al. observed that toxemia produced a marked and in several instances highly significant reduction in jaundice. Several authors have reported an increased incidence of neonatal hyperbilirubinemia following induction of labor with oxytocin.,,,,,
Aims and objectives
- To ascertain the prevalence of neonatal hyperbilirubinemia with serum bilirubin level of 12 mg/dL or more in full-term neonates
- To establish correlation of various maternal factors with hyperbilirubinemia, for example, age, gestation, parity gestational diabetes, oxytocin-induced labor, and delivery.
| Materials and Methodology|| |
It was a prospective, cross-sectional study conducted from July 2012 to August 2014 at Dr. D. Y. Patil Medical College, Pimpri, Pune. A total of 2000 healthy term deliveries were screened, out of which 100 neonates with exaggerated hyperbilirubinemia were included. Review of literature shows range of exaggerated physiological hyperbilirubinemia in various studies ranges from <6% to >20%., In the present study, 10% incidence of hyperbilirubinemia was taken for the estimation of the sample size. With this 10% proportion and 95% confidence interval of 6%, the sample calculated was 96 using the WHO/CDC statistical package Epi Info 7 (Centers for Disease Control and Prevention (CDC), Atlanta, Georgia (US)). Hence, we included 100 neonates in the study.
All full-term newborns admitted in the PNC ward with serum bilirubin levels more than 12 mg/dL.
Preterm babies/low birth weight babies, postterm babies, babies with major illness (Rh and ABO incompatibility), or admitted in Neonatal Intensive Care Unit.
Newborns with serum bilirubin >12 mg/dL were evaluated for the maternal factors such as age, parity, gestation, history of diabetes and toxemia, and oxytocin infusion. Informed consent was obtained from the parents of the newborn and examination was carried out in the PNC ward. All the details were noted on the pro forma. Serum bilirubin estimation was done by Diazo technique. The data were analyzed using t-test (for parametric distributions).
| Results|| |
During the period of study, 330 babies out of 2000 deliveries had achieved the serum bilirubin level of >12 mg/dL. Thus, the prevalence of exaggerated neonatal hyperbilirubinemia in the current study was 16.5%.
Out of the 100 neonates studied, 27 mothers were above >30 years, and 73 mothers were <30 years. Parity of the mothers included in the study ranged from P1–P4. However, 51 of them were primigravida and 49 were multipara [Table 1].
|Table 1: Distribution according to maternal age and parity in the study group|
Click here to view
Out of 82 mothers, 9% had diabetes mellitus.
Preeclampsia was detected in 17% of the mothers.
About 5% mothers had maternal infection.
Oxytocin was used for the augmentation of labor in about 51% of the mothers [Table 2].
When serum bilirubin was compared to maternal age, Z = 0.06 and P> 0.05 which shows no statistical correlation between the two factors [Table 3].
|Table 3: Comparison of serum bilirubin according to maternal age in the study group|
Click here to view
Z = 1.09 and P is > 0.05 which is statistically not significant [Table 4].
|Table 4: Comparison of serum bilirubin according to parity in the study group|
Click here to view
The current study showed no correlation between maternal toxemia, and exaggerated physiological jaundice as Z = 0.02 and P> 0.05.
Maternal diabetes was also not found to be statistically significant (P > 0.05), because perhaps the sample size was limited (only 9 diabetic mothers). However, there is strong association between maternal infection and serum bilirubin even when only 5 mothers had infection (Z = 2.31 and P < 0.05) [Table 5].
|Table 5: Comparison of serum bilirubin according to maternal toxemia, diabetes, and infection in the study group|
Click here to view
Z = 1.17 and P> 0.05 which shows no statistical correlation [Table 6].
|Table 6: Comparison of serum bilirubin according to oxytocin infusion in the study group|
Click here to view
| Discussion|| |
The incidence of hyperbilirubinemia over 12 mg/dL in newborn infants has been reported in several studies, the range of reported values in various studies ranges from <6% to >20%., In the present study, 16.5% of neonates were found to have exaggerated neonatal hyperbilirubinemia, while Jeffares  reported the incidence of neonatal jaundice to be 8.6%, Maisels  found it to be 15.5%. In the previous studies done by Jone in Lucknow, Mumbai, and Pune, the incidence of physiological jaundice was observed to be 57%, 25.3%, and 47.2%, respectively. A higher incidence of hyperbilirubinemia (10.3%) was reported by Agarwal et al.
There are conflicting reports regarding the influence of maternal age on neonatal hyperbilirubinemia. In the current study, 27% of mothers are under 30 years of maternal age and 73% were over 30 years of maternal age and insignificant correlation was found with hyperbilirubinemia which is similar to the study of Osborn et al. and Linn et al. Such an incidence was observed in our study, probably due to high number of pregnant mothers over 30 years of age. On the contrary, a decline in the incidence of neonatal hyperbilirubinemia with advancing maternal age was observed by Wood et al. (90.5% <30 years of age and 79.5% >30 years of maternal age).
In the present study, the correlation between neonatal serum bilirubin levels and maternal parity was found to be insignificant (P > 0.05). This result was similar to the study of Wood et al. and Brown and Boon  conducted a study in Chinese women and observed, a slight increase in neonatal serum bilirubin levels with increasing parity. While Linn  and Osborn et al. (P = 0.780) did not observe such a correlation in their study.
A study on epidemiology of neonatal jaundice was conducted by Gale et al., at Jerusalem among 1081 neonates and observed that among all the neonates born to diabetic mothers, 0.17% newborns had serum bilirubin <12 mg/dL, while 1.56% had serum bilirubin >12.9 mg/dL, proving that high-serum bilirubin was associated with maternal diabetes mellitus. About 57.7% of newborns born to a mother with gestational diabetes mellitus were found to have neonatal hyperbilirubinemia in the study of Varghese et al., Farooq et al. in his study of complications associated with gestational diabetes found the occurrence of jaundice in 9 out of 50 cases (18%). Joy and Sivakumar  in their study observed that 35.13% of babies had hyperbilirubinemia. In the current study, P value is > 0.05, therefore, difference is not statistically significant because perhaps the sample size was limited (100), out of which only 9 diabetic mothers were included in the study.
In our study, it was observed that toxemia has no influence on neonatal hyperbilirubinemia. Similarly, in Shailinn's study, toxemia was not related to the occurrence of neonatal hyperbilirubinemia (odds ratio 0.86,95% confidence interval 0.76–1.11). Maisels et al., in his study on neonatal jaundice and maternal hypertension observed no significant association (P = 0.332), while Wood et al. found that severity of jaundice is reduced in neonates born to mothers with toxemia. Guruvare and Kushtagi  concluded that in mothers with severe preeclampsia, 29.1% of the newborns had physiological jaundice.
In the current study, a strong association was found between maternal infection and neonatal hyperbilirubinemia (P ≤ 0.05), although only 5 mothers had evidence of maternal infection. On the contrary, Bajpai et al. in his study did not report any case due to infection or sepsis.
Earlier studies on neonatal hyperbilirubinemia had shown a potential association between the use of oxytocin to induce or augment labor and neonatal hyperbilirubinemia. Several investigators have reported an increased incidence of neonatal hyperbilirubinemia following induction of labor with oxytocin. Gould et al. and Wood et al., in their studies failed to reveal any significant difference between the incidence of neonatal hyperbilirubinemia following spontaneous labor and after labor induced by oxytocin. On the contrary, Smith and Wilson  and Friedman et al. have found small effect of oxytocin in producing neonatal hyperbilirubinemia. Ghosh and Hudson  in their study failed to find any correlation between neonatal hyperbilirubinemia and delivery accelerated by oxytocin. Singhi and Singh  found 20% of cases due to oxytocin-induced jaundice, but no relation between oxytocin dose and serum bilirubin at 72 h. Jeffares MJ  are also of the view that oxytocin administration during labor does not alter the incidence of neonatal jaundice. Similar result was found in the current study (n = 51, P> 0.05). Oxytocin if administered with dextrose is known to cause jaundice in newborns as suggested by Wasserstrum  since in our hospital oxytocin is administered along with RL solution, the possibility of hyperbilirubinemia was decreased.
| Conclusions|| |
Maternal infection was found to have a significant effect on neonatal exaggerated hyperbilirubinemia. Therefore, interventions should be prioritized to prevent maternal sepsis. The first approach targets facility-based deliveries and requires increased provision and uptake of proper antenatal care early in pregnancy. In the community, clean delivery practices should be prioritized. In referral centers with high-risk populations, new strategies should be developed, particularly the identification of risk factors for maternal and neonatal sepsis which can be prevented through antibiotic prophylaxis and other measures.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Simon HN. A Study to Assess the Factors Affecting Neonatal Jaundice and the Impact of the Same, on Growth and Development of Children Less than 3 Years, Attending the Out-patient Department at a Selected Hospital Kolar; 2007. p. 3.
Whaley, Wong. Nursing Care of Infants and Children. St. Louis: C.V. Mosby Company; 1979. p. 153-60.
Neonatal Hyperbilirubinemia. In: Taeusch HW, Ballard RA, Gleason CA. Avery's diseases of the new born. 8th Ed. Elsevier Saunders 2004: 1226-56.
Behrman RE, Vaughan VC 3rd
, Nelson WE, editors. Nelson's Textbook of Pediatrics. 12th
ed. Philadelphia: Saunders; 1983.
Wood BS, Culley PE, Waterhouse JA, Powell DJ. Factors influencing neonatal jaundice. Arch Dis Child 1962;37:371-7.
Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, Ryan KJ, et al.
Epidemiology of neonatal hyperbilirubinemia. Pediatrics 1985;75:770-4.
Taylor PM, Wolfson JH, Bright NH, Birchard EL, Derinoz MN, Watson DW, et al.
Hyperbilirubinemia in infants of diabetic mothers. Biol Neonat 1963;5:289-98.
Yamanouchi I, Yamauchi Y, Igarashi I. Transcutaneous bilirubinometry: Preliminary studies of noninvasive transcutaneous bilirubin meter in the Okayama National Hospital. Pediatrics 1980;65:195-202.
Campbell N, Harvey D, Norman AP. Increased frequency of neonatal jaundice in a maternity hospital. Br Med J 1975;2:548-52.
Chew WC, Swann IL. Influence of simultaneous low amniotomy and oxytocin infusion and other maternal factors on neonatal jaundice: A prospective study. Br Med J 1977;1:72-3.
Friedman L, Lewis PJ, Clifton P, Bulpitt CJ. Factors influencing the incidence of neonatal jaundice. Br Med J 1978;1:1235-7.
Jeffares MJ. A multifactorial survey of neonatal juandice. Br J Obstet Gynaecol 1977;84:452-5.
Maisels MJ, Leib G, Gifford K, Antle C. The “yellow baby syndrome”. Pediatr Res 1985;19:240.
Sima DG, Neligan GA. Factors affecting the increasing incidence of severe non-haemolytic neonatal jaundice. Br J Obstet Gynaecol 1975;82:863-7.
Maisels MJ, Gifford K. Normal serum bilirubin levels in the newborn and the effect of breast-feeding. Pediatrics 1986;78:837-43.
Valaes T, Petmezaki S, Doxiadis SE. Effect on neonatal hyperbilirubinemia of phenobarbital during pregnancy or after birth: Practical value of the treatment in a population with high risk of unexplained severe neonatal jaundice. In: Bergsma D, editor. Bilirubin Metabolism in the Newborn (Birth Defects, Original Articles Series). Vol. 6. Baltimore: Williams and Wilkin (for National Foundation- March of Dimes); 1970. p. 46.
Maisels MJ, Gifford K. Neonatal jaundice in full-term infants. Role of breast-feeding and other causes. Am J Dis Child 1983;137:561-2.
Bajpai PC, Misra PK, Agarwal M, Engineer AD. An etiological study of neonatal hyperbilirubinaemia. Indian J Pediatr 1971;38:424-9.
Merchant RH, Merchant SM, Babar ST. A study of 75 cases of neonatal jaundice. Indian Pediatr 1975;12:889-93.
Anand VR, Magotra ML. Neonatal jaundice: Its incidence and aetiology. Indian Pediatr 1978;15:155-60.
Agarwal R, Kaushal M, Aggarwal R, Paul VK, Deorari AK. Early neonatal hyperbilirubinemia using first day serum bilirubin level. Indian Pediatr 2002;39:724-30.
Osborn LM, Reiff MI, Bolus R. Jaundice in the full-term neonate. Pediatrics 1984;73:520-5.
Wood B, Culley P, Roginski C, Powell J, Waterhouse J. Factors affecting neonatal jaundice. Arch Dis Child 1979;54:111-5.
Brown WR, Boon WH. Ethnic group differences in plasma bilirubin levels of full-term, healthy Singapore newborns. Pediatrics 1965;36:745-51.
Gale R, Seidman DS, Dollberg S, Stevenson DK. Epidemiology of neonatal jaundice in the Jerusalem population. J Pediatr Gastroenterol Nutr 1990;10:82-6.
Varghese R, Thomas B, Al Hail M, Rauf A, Al Sadi M, Al Sualiti A, et al
. The prevalence, risk factors, maternal and fetal outcomes in gestational diabetes mellitus. Int J Drug Dev Res 2012;4:356-68.
Farooq MU, Ayaz A, Ali Bahoo L, Ahmad I. Maternal and neonatal outcomes in gestational diabetes mellitus. Int J Endocrinol Metab 2007;3:109-15.
Joy R, Sivakumar V. A prospective study on the effect of gestational diabetes mellitus on maternal and fetal outcome. Int J Pharm Teach Pract 2012;3:345-51.
Maisels MJ, Gifford K, Antle CE, Leib GR. Jaundice in the healthy newborn infant: A new approach to an old problem. Pediatrics 1988;81:505-11.
Guruvare S, Kushtagi P. Observations of Expectant Management in Severe Preeclampsia between 24 to 36 Weeks of Pregnancy. National Neonatology Forum of India; 2008.
Gould SR, Mountrose U, Brown DJ, Whitehouse WL, Barnardo DE. Influence of previous oral contraception and maternal oxytocin infusion on neonatal jaundice. Br Med J 1974;3:228-30.
Smith MN, Wilson RG. Oxytocin and neonatal jaundice. Br Med J 1978;1:50.
Ghosh A, Hudson FP. Oxytocic agents and neonatal hyperbilirubinaemia. Lancet 1972;2:823.
Singhi S, Singh M. Pathogenesis of oxytocin-induced neonatal hyperbilirubinaemia. Arch Dis Child 1979;54:400-2.
Wasserstrum N. Issues in fluid management during labor: General considerations. Clin Obstet Gynecol 1992;35:505-13.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]